Price$1.31-0.14 (-9.31%)
2026-04-212026-07-24
News · 26 weeks19-60%
2026-01-252026-07-19
Mix1290d
- Other5(42%)
- SEC Filings4(33%)
- Insider3(25%)
Latest news
25 items- PRMediciNova Announces Patient Enrollment Milestone Achieved in SEANOBI Study Expanded-Access-Program Evaluating MN‑166 (ibudilast) in ALS patientsLA JOLLA, Calif., July 15, 2026 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the Standard Market of the Tokyo Stock Exchange (Code Number: 4875), today announced that the target enrollment of 200 patients has been achieved in the SEANOBI-ALS study (Scalable Expanded Access with Analysis of Neurofilament and Other Biomarkers in ALS ; NCT 06743776) evaluating MN‑166 (ibudilast) in patients with amyotrophic lateral sclerosis (ALS). The Expanded Access Program SEANOBI study is funded by National Institute of Neurological Disorders and Stroke (NINDS) National Institutes of Health (NIH) supported under the ACT for ALS. Th
- PRMediciNova CEO Provides Shareholder UpdateLA JOLLA, Calif., June 30, 2026 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the Standard Market of the Tokyo Stock Exchange (Code Number: 4875), today provides shareholders a corporate update in the following Letter to Stockholders from CEO Yuichi Iwaki, M.D., Ph.D. Dear Fellow Shareholders, MediciNova continues to make significant progress across its key programs, most recently anchored by the completion of the last patient last visit in our Phase 2 clinical trial of MN-001-NATG-202 evaluating MN-001 (tipelukast) for the treatment of hypertriglyceridemia and nonalcoholic fatty liver disease (NAFLD) associated wit
- INSIDERSEC Form 4 filed by Director Nagao Hideki4 - MEDICINOVA INC (0001226616) (Issuer)
- INSIDERSEC Form 4 filed by Director Lemerond Nicole4 - MEDICINOVA INC (0001226616) (Issuer)
- INSIDERSEC Form 4 filed by Director Beaver Carolyn4 - MEDICINOVA INC (0001226616) (Issuer)
- SECMedicinova Inc filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders8-K - MEDICINOVA INC (0001226616) (Filer)
- PRMediciNova Receives Notice of Allowance for New Patent Covering Use of MN-166 in Combination with Anti-PD-1 Immune Checkpoint Inhibitor for Glioblastoma TreatmentLA JOLLA, Calif., June 08, 2026 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the Standard Market of the Tokyo Stock Exchange (Code Number: 4875), today announced that it has received a Notice of Allowance from the U.S. Patent and Trademark Office for a pending patent application that covers the use of ibudilast (MN-166) in combination with an immune checkpoint inhibitor, specifically an anti-PD-1 antibody, for the treatment of glioblastoma. This patent allowance is expected to further strengthen the intellectual property position supporting the Company's combination therapy development strategy. Kazuko Matsuda, MD,
- PRMediciNova Announces Completion of Last Patient Last Visit in the MN-001-NATG-202 Clinical Trial of MN-001 (Tipelukast)LA JOLLA, Calif., May 26, 2026 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the Standard Market of the Tokyo Stock Exchange (Code Number: 4875), today announced the completion of last patient last visit (LPLV) in its Phase 2 clinical trial, MN-001-NATG-202, evaluating MN-001 (tipelukast) for the treatment of hypertriglyceridemia and nonalcoholic fatty liver disease (NAFLD) associated with type 2 diabetes mellitus (T2DM). The MN-001-NATG-202 study is a multicenter, randomized, double-blind, placebo-controlled trial evaluating MN-001 (tipelukast). Patients were randomized 1:1 to receive either 500 mg/day of MN-001 (ti
- SECSEC Form 10-Q filed by Medicinova Inc10-Q - MEDICINOVA INC (0001226616) (Filer)
- SECSEC Form DEFA14A filed by Medicinova IncDEFA14A - MEDICINOVA INC (0001226616) (Filer)
- SECSEC Form DEF 14A filed by Medicinova IncDEF 14A - MEDICINOVA INC (0001226616) (Filer)
- PRNew Peer‑Reviewed Study Reveals Actionable Immune–Microenvironment Target in Brain Metastasis; Medicinova Advances Clinical TranslationLA JOLLA, Calif., April 27, 2026 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the Standard Market of the Tokyo Stock Exchange (Code Number: 4875), today announced that a study conducted by researchers at the Spanish National Cancer Research Centre (CNIO) has identified macrophage migration inhibitory factor (MIF)–mediated reprogramming of CD74‑positive microglia and macrophages as a central vulnerability in brain metastasis. The research, recently published in the peer‑reviewed journal "Cancer Research" (March 2026), demonstrates pharmacological modulation of this pathway using the brain‑penetrant small molecule ibud
- SECSEC Form PRER14A filed by Medicinova IncPRER14A - MEDICINOVA INC (0001226616) (Filer)
- SECSEC Form PRE 14A filed by Medicinova IncPRE 14A - MEDICINOVA INC (0001226616) (Filer)
- ANALYSTH.C. Wainwright initiated coverage on MediciNova with a new price targetH.C. Wainwright initiated coverage of MediciNova with a rating of Buy and set a new price target of $10.00
- PRMediciNova to Participate at the 38th Annual ROTH ConferenceLA JOLLA, Calif., March 16, 2026 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the Standard Market of the Tokyo Stock Exchange (Code Number: 4875) (the "Company"), announces that Yuichi Iwaki, M.D., Ph.D., President and CEO, and David H. Crean, Ph.D., Chief Business Officer will participate at the 38th Annual ROTH Conference. The conference is being held on March 22 – 24, 2026 at The Ritz-Carlton Laguna Niguel in Dana Point, CA. Drs. Iwaki and Crean will host one-on-one and small group meetings with investors and provide company updates. Investors interested in arranging a meeting should contact their representatives
- SECSEC Form 10-K filed by Medicinova Inc10-K - MEDICINOVA INC (0001226616) (Filer)
- SECSEC Form 8-K filed by Medicinova Inc8-K - MEDICINOVA INC (0001226616) (Filer)
- PRMediciNova Announces 100 Patients Enrolled in SEANOBI Study Expanded-Access-Program (EAP) Evaluating MN‑166 (ibudilast) in ALS patientsLA JOLLA, Calif., Jan. 29, 2026 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the Standard Market of the Tokyo Stock Exchange (Code Number: 4875), today announced that as of the end of January 2026, 12 sites in the US are activated and 100 patients have been enrolled in the SEANOBI study (Scalable Expanded Access with Analysis of Neurofilament and Other Biomarkers in ALS; NCT 06743776) representing 50% of the planned 200-enrollment, evaluating MN‑166 (ibudilast) in patients with amyotrophic lateral sclerosis (ALS). Dr. Yuichi Iwaki, President and CEO of MediciNova, commented: "Achieving 100 enrolled patients in the N
- INSIDERSEC Form 4 filed by Chief Medical Officer Matsuda Kazuko4 - MEDICINOVA INC (0001226616) (Issuer)
- INSIDERSEC Form 4 filed by President and CEO Iwaki Yuichi4 - MEDICINOVA INC (0001226616) (Issuer)
- PR2026 New Year's Greetings from the CEOLA JOLLA, Calif., Jan. 06, 2026 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the Standard Market of the Tokyo Stock Exchange (Code Number: 4875) provides shareholders a corporate update in the following Letter to Stockholders from CEO Yuichi Iwaki, M.D., Ph.D. Dear Fellow Shareholders, The year 2025 was marked by global uncertainty, with accelerating inflation, evolving U.S. trade policies under the new administration, and persistent geopolitical risks. Despite these challenges, MediciNova achieved significant milestones, including completion of patient enrollment in three clinical trials and the launch of a large-
- SECSEC Form 424B5 filed by Medicinova Inc424B5 - MEDICINOVA INC (0001226616) (Filer)
- SECSEC Form 8-K filed by Medicinova Inc8-K - MEDICINOVA INC (0001226616) (Filer)
- PRMediciNova Announces Completion of Patient Enrollment Evaluating MN-166 (ibudilast) in the Prevention of Chemotherapy-induced Peripheral NeuropathyLA JOLLA, Calif., Dec. 18, 2025 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the Standard Market of the Tokyo Stock Exchange (Code Number: 4875), today announced the successful completion of patient enrollment in the randomized, placebo-controlled Phase 2 clinical trial, the OXTOX study (Oxaliplatin Neurotoxicity study in patients with metastatic colorectal cancer). This study, an investigator-initiated clinical trial led by Dr. Janette Vardy and Dr. Haryana Dhillon, is evaluating MN-166 (ibudilast) for the prevention of chemotherapy-induced peripheral neuropathy in patients with metastatic colorectal cancer. A total
MNOV FAQ
6 questionsWhat does Medicinova Inc do?
MediciNova, Inc., a biopharmaceutical company, focuses on developing novel and small molecule therapeutics for the treatment of serious diseases with unmet medical needs in the United States. The company is developing MN-166 (ibudilast), an oral anti-inflammatory and neuroprotective agent for treating neurological disorders, such as primary and secondary progressive multiple sclerosis, amyotrophic lateral sclerosis, chemotherapy-induced peripheral neuropathy, degenerative cervical myelopathy, glioblastoma, and substance dependence and addiction. Its product pipeline also includes MN-221...Where does MNOV stock trade?
Medicinova Inc (MNOV) is listed on NASDAQ.What sector and industry is MNOV in?
Medicinova Inc operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.What are analysts saying about MNOV?
Medicinova Inc has had 1 recent analyst action on file. The most recent action was from H.C. Wainwright: Buy with a $1000.00 price target on 2026-03-16. Recent price targets cluster around $1000.00.What companies are similar to MNOV?
Notable peers in the same industry include LLY (Eli Lilly and Company), JNJ (Johnson & Johnson), ABBV (AbbVie Inc.), MRK (Merck & Company Inc.), NVS (Novartis AG). Compare MNOV side-by-side with any of them on Quantisnow.How can I track MNOV on Quantisnow?
Quantisnow aggregates Medicinova Inc's SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow MNOV to receive live email and push alerts on every new disclosure.